

You're invited to



FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)


What If You Could Get to the Root of IL-23 Inflammation in UC?¹⁻³

TREMFYA® binds to IL-23, inhibiting the release of proinflammatory cytokines and chemokines. CD64+ cells are the predominant source of IL-23 in UC. The clinical significance of these findings is unknown.^{1,2,4}

Explore the MOA



Data rates may apply.



This program/event is developed and offered by Johnson and Johnson. This is not an official program/event of the Cleveland Clinic.

For illustrative purposes only.



Lukasz Kwapisz, MD

Gastroenterologist
Miami, FL



Monday, March 17, 2025

12:30 PM - 1:15 PM Eastern



Live Product Theater at the Cleveland Clinic Gut Insights Conference

Margaritaville Hollywood Beach Resort, 1111 N Ocean Dr, Hollywood, FL 33019

CD64+=cluster of differentiation 64 plus; IL-23=interleukin-23; MOA=mechanism of action.

1. Atreya R, et al. Poster #P504. Presented at: 2023 Congress of the European Crohn's and Colitis Organization. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Sewell GW, Kaser A. *J Crohns Colitis*. 2022;16(suppl 2):ii3-ii19. 4. Krueger JG, et al. *Front Immunol*. 2024;15:1331217.

INDICATIONS

TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

DOSAGE AND ADMINISTRATION

TREMFYA® is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at Weeks 0 and 4. In active psoriatic arthritis, TREMFYA® may be administered alone or in combination with a cDMARD (eg, methotrexate).

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.

cDMARD, conventional disease-modifying antirheumatic drug.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported. TREMFYA® may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a clinically important or serious infection develops, discontinue TREMFYA® until infection resolves. Evaluate for tuberculosis before treating with TREMFYA®. Avoid use of live vaccines in patients treated with TREMFYA®. Please see related and other Important Safety Information at right.

DISCLOSURES

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Janssen Biotech, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

SPONSORED BY JANSSEN BIOTECH, INC.

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the Congress of Clinical Rheumatology.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections

TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations

Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS

Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the enclosed full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

Johnson & Johnson

© Janssen Biotech, Inc. 2024 09/24 cp-463150v1
Janssen Biotech, Inc., a Johnson & Johnson company, 800 Ridgeview Drive, Horsham, PA 19044